This week, it was formally announced that Daniel H. Solomon, Professor at Harvard Medical School (Boston, USA) will be an official visiting professor at the REMEDY research center.
- "This is a fantastic strength for REMEDY and Diakonhjemmet Hospital," says Espen A. Haavardsholm, Head of Center at REMEDY and Head of Research and Innovation at the hospital.
In addition to his role at Harvard, Dr. Solomon is Chair of the Section of Clinical Sciences in Rheumatology at Brigham and Women's Hospital, where he is also a member of the Division of Pharmacoepidemiology and Pharmacoeconomics. The focus of his research includes clinical trials, health services research, quality of care, and pharmacoepidemiology in rheumatic diseases and osteoporosis. He is editor-in-chief of the renowned journal Arthritis and Rheumatology.
- Having such an international capacity as part of our academic community provides unique opportunities to discuss new projects and results. We have collaborated with Dan Solomon for many years, and are pleased that the collaboration is now being further developed. Among other things, Solomon will be present at Diakonhjemmet for a week in March, where he will give an open lecture, participate in a research seminar, and contribute to a number of activities especially aimed at younger researchers, says Haavardsholm.
Siri Lillegraven, Deputy Head of REMEDY and Head of the Clinical Research Unit, has previously worked for two years in Solomon's research group in Boston, USA. She says that he has a broad academic interest, which is reflected in the fact that he has been central to a large number of important studies and has an extensive list of publications, with over 800 scientific articles. At the same time, Solomon is particularly known for being a good mentor for younger researchers, and has received several awards in recognition of this.
Initially, Solmon is affiliated with REMEDY as a visiting professor for one year, with the possibility of an extension for another year. The visiting professorship is formally affiliated with the Department of Clinical Medicine at the University of Oslo, which is also a partner in REMEDY.